Jiangsu Hengrui Medicine
600276.SS
#449
Rank
A$76.88 B
Marketcap
A$11.55
Share price
1.73%
Change (1 day)
5.78%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2025 (TTM): A$0.19

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is A$0.18. In 2024 the company made an earnings per share (EPS) of A$0.19 an increase over its 2023 EPS that were of A$0.13.

EPS history for Jiangsu Hengrui Medicine from 2000 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$0.190.32%
2024A$0.1942.43%
2023A$0.138.77%
2022A$0.12-20.62%
2021A$0.16-26.59%
2020A$0.2127.24%
2019A$0.1728.41%
2018A$0.1320.04%
2017A$0.1131.21%
2016A$0.0824111.46%
2015A$0.0739436.27%
2014A$0.0542619.77%
2013A$0.0453018.05%
2012A$0.0383823.9%
2011A$0.0309726.9%
2010A$0.0244112.37%
2009A$0.0217256.6%
2008A$0.013879.18%
2007A$0.01270114.48%
2006A$0.00592464.83%
2005A$0.00359435.55%
2004A$0.00265129.73%
2003A$0.00204419.86%
2002A$0.001705-2.71%
2001A$0.0017531.02%
2000A$0.001735